Sangamo stock plummets 50% after Pfizer ends gene therapy deal

Tue, Dec 31, 2024, 7:56 AM

Sangamo Therapeutics Inc. (SGMO) shares plunged in Tuesday's pre-market trading by over 50% after Pfizer Inc. (PFE) terminated its partnership with the company. The two were collaborating on a gene therapy program to co-develop a treatment for hemophilia A. Sangamo is exploring "all options" to continue the program.

Morning Brief co-hosts Madison Mills and Seana Smith break down the details.

To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

This post was written by Angel Smith